Restless Legs Syndrome (RLS): Symptoms, Causes, Diagnosis, and Evidence-Based Treatments

Restless Legs Syndrome (RLS), also known as Willis-Ekbom Disease, is a neurological sensorimotor disorder characterized by an uncomfortable and often irresistible urge to move the legs. This urge typically occurs during periods of rest or inactivity — particularly in the evening and nighttime hours — and is temporarily relieved by movement such as walking, stretching, or shifting position.

RLS is classified in the DSM-5-TR as a sleep-wake disorder, reflecting its profound impact on sleep onset, sleep quality, and daytime functioning. The International Classification of Sleep Disorders (ICSD-3) similarly recognizes it as a significant sleep-related movement disorder. While it is fundamentally a neurological condition, its consequences extend deeply into psychological well-being, contributing to insomnia, fatigue, mood disturbance, impaired concentration, and diminished quality of life.

Prevalence estimates vary across populations, but research consistently suggests that RLS affects approximately 5–15% of the general adult population in Western countries, with clinically significant symptoms (occurring at least twice per week with moderate-to-severe distress) affecting roughly 2–3%. The condition occurs across all age groups but becomes more common and often more severe with advancing age. Women are approximately twice as likely as men to be affected, a disparity that may be partly related to hormonal factors and iron metabolism differences associated with pregnancy and menstruation.

Despite its high prevalence, RLS remains significantly underdiagnosed. Many individuals dismiss their symptoms as mere restlessness, growing pains (in children), or nervousness. Others may not report symptoms to their healthcare providers because they do not recognize the pattern as a medical condition. This diagnostic gap is particularly concerning given the availability of effective treatments and the substantial burden RLS places on sleep and mental health.

The hallmark of Restless Legs Syndrome is an uncomfortable sensation in the legs accompanied by an overwhelming urge to move them. The DSM-5-TR and the International Restless Legs Syndrome Study Group (IRLSSG) identify five essential diagnostic criteria, all of which must be present:

• An urge to move the legs, usually accompanied or caused by uncomfortable and unpleasant sensations in the legs. Some individuals experience the urge to move without a clearly identifiable sensation.
• Symptoms begin or worsen during periods of rest or inactivity, such as lying down, sitting, or reclining.
• Symptoms are partially or totally relieved by movement, such as walking, stretching, or bending the legs, at least as long as the activity continues.
• Symptoms occur exclusively or predominantly in the evening or night, or are worse during those times than during the day.
• Symptoms are not solely attributable to another medical or behavioral condition, such as leg cramps, positional discomfort, habitual foot tapping, or peripheral neuropathy.

Individuals describe the sensations in a variety of ways, often struggling to find adequate words. Common descriptions include:

• Crawling or creeping sensations deep inside the legs
• Tingling, itching, or "pins and needles"
• A pulling, tugging, or aching feeling
• A sensation likened to "electricity" or "fizzing" under the skin
• An internal restlessness that is difficult to localize precisely

These sensations most commonly affect the calves and lower legs but can also involve the thighs, feet, and — in some cases — the arms, trunk, or even the face. Symptoms are typically bilateral, though they may alternate sides or be more prominent on one side.

Associated features and warning signs that warrant attention include:

• Periodic Limb Movements of Sleep (PLMS): Approximately 80–90% of individuals with RLS also experience repetitive, involuntary jerking or twitching movements of the legs (and sometimes arms) during sleep. These movements occur in episodes, typically every 15–40 seconds, and can significantly fragment sleep — often without the person's awareness.
• Chronic insomnia: Difficulty falling asleep is one of the most distressing consequences of RLS. The compulsion to move prevents the stillness needed for sleep onset, and many individuals report lying awake for hours.
• Daytime fatigue and sleepiness: Poor sleep quality leads to exhaustion, difficulty concentrating, memory problems, and reduced productivity.
• Mood disturbance: Chronic sleep deprivation and the persistent discomfort of RLS are strongly associated with irritability, anxiety, and depressive symptoms. Research suggests that individuals with RLS have significantly higher rates of depression and anxiety disorders compared to the general population.
• Impaired quality of life: Long-distance travel, attending movies or theater, sitting in meetings, or any prolonged sedentary activity can become dreaded or avoided entirely.

The precise pathophysiology of Restless Legs Syndrome is not fully understood, but converging lines of evidence point to disruptions in dopaminergic signaling and brain iron metabolism as central mechanisms. RLS is broadly categorized into two forms:

Primary (Idiopathic) RLS has no identifiable underlying medical cause and is believed to have a strong genetic basis. Research has identified several gene variants — including BTBD9, MEIS1, MAP2K5, and PTPRD — that are associated with increased susceptibility. If a first-degree relative has RLS, an individual's risk is three to six times higher than that of the general population. Primary RLS often begins before age 40 and tends to progress gradually over the lifespan.

Secondary RLS occurs in association with another medical condition or factor, and addressing the underlying cause can sometimes resolve or significantly improve symptoms. Key secondary causes and risk factors include:

• Iron deficiency: This is the single most well-established and clinically important risk factor. Even when serum iron levels appear normal, individuals with RLS often have reduced iron stores in the brain, particularly in the substantia nigra — a region critical for dopamine production. Serum ferritin levels below 50–75 µg/L are considered a threshold below which RLS symptoms may emerge or worsen.
• End-stage renal disease (ESRD): RLS affects an estimated 20–30% of patients on dialysis, likely related to iron metabolism disruption, uremic toxins, and other metabolic derangements.
• Pregnancy: RLS symptoms develop in approximately 20–30% of pregnant women, most commonly in the third trimester, and typically resolve within weeks of delivery. Iron and folate depletion, hormonal shifts, and circulatory changes all likely contribute.
• Peripheral neuropathy: Damage to peripheral nerves, from conditions such as diabetes, can produce or exacerbate RLS symptoms.
• Medications: Several classes of commonly prescribed medications can trigger or worsen RLS, including antidepressants (particularly SSRIs and SNRIs), antipsychotics, antihistamines (especially sedating types like diphenhydramine), and anti-nausea drugs such as metoclopramide.
• Caffeine, alcohol, and nicotine: These substances can exacerbate symptoms in susceptible individuals, though the relationship is complex and varies by person.

The dopamine hypothesis remains the most robust neurobiological framework for understanding RLS. Dopamine is a neurotransmitter critical for regulating movement, and its function follows a circadian rhythm — with levels naturally declining in the evening and night. This circadian decline aligns precisely with the characteristic worsening of RLS symptoms. Iron is an essential cofactor for tyrosine hydroxylase, the enzyme that synthesizes dopamine, providing a mechanistic link between iron deficiency and dopaminergic dysfunction in RLS.

Restless Legs Syndrome is diagnosed clinically — meaning there is no blood test, imaging study, or sleep study that can definitively confirm or rule out the diagnosis. Diagnosis rests primarily on a thorough clinical history that establishes the presence of all five IRLSSG essential criteria described above.

A qualified healthcare provider — typically a neurologist, sleep medicine specialist, or primary care physician with relevant expertise — will conduct the evaluation, which generally includes:

• Detailed symptom history: The clinician will ask about the nature, location, timing, triggers, and relieving factors for leg sensations. They will inquire about sleep quality, daytime functioning, family history, and the impact of symptoms on daily life.
• Medication review: A careful review of all current medications, supplements, and substance use is essential to identify potential pharmacological contributors.
• Physical and neurological examination: This helps rule out conditions that mimic RLS, such as peripheral neuropathy, venous insufficiency, arthritis, or musculoskeletal pain.
• Laboratory testing: Blood work is typically ordered to assess serum ferritin (the most important lab value in RLS evaluation), complete blood count, iron studies (serum iron, total iron-binding capacity, transferrin saturation), kidney function, thyroid function, and blood glucose or HbA1c. A ferritin level below 75 µg/L in the context of RLS symptoms is generally considered clinically significant and warrants iron supplementation.
• Polysomnography (sleep study): While not required for diagnosis, a sleep study may be recommended if there is concern about coexisting sleep disorders such as obstructive sleep apnea, or to document periodic limb movements of sleep (PLMS) and assess their impact on sleep architecture.

Differential diagnosis is a critical step. Several conditions can produce symptoms that superficially resemble RLS but require different management:

• Nocturnal leg cramps: These involve painful, involuntary muscle contractions rather than an urge to move.
• Peripheral neuropathy: Burning, numbness, or tingling that does not necessarily worsen with rest or improve with movement.
• Positional discomfort: Numbness or discomfort from prolonged sitting that resolves with position change rather than with ongoing movement.
• Akathisia: A generalized inner restlessness often associated with antipsychotic medications, not specifically tied to the legs or to a circadian pattern.
• Venous insufficiency: Leg heaviness and discomfort that worsens with standing and improves with leg elevation, rather than with walking.

Severity is often assessed using the International Restless Legs Syndrome Study Group Rating Scale (IRLS), a validated 10-item questionnaire that quantifies symptom severity, frequency, impact on sleep, daytime functioning, and mood. Scores range from 0 to 40, with scores of 21–30 indicating severe and 31–40 very severe RLS.

Treatment for Restless Legs Syndrome is guided by symptom severity, frequency, impact on quality of life, and the presence of underlying contributing factors. The approach typically begins with non-pharmacological strategies and iron repletion, with medications reserved for moderate-to-severe cases.

1. Addressing Underlying Causes

Before initiating symptomatic treatment, it is essential to identify and address contributing factors:

• Iron supplementation: If serum ferritin is below 75 µg/L, oral iron supplementation (typically ferrous sulfate 325 mg with vitamin C to enhance absorption, taken on an empty stomach) is recommended as a first-line intervention. For individuals who cannot tolerate oral iron or who have very low ferritin levels, intravenous iron infusion may be more appropriate. Iron repletion alone can substantially reduce or eliminate symptoms in many patients.
• Medication adjustment: If a medication is identified as a likely contributor (e.g., an SSRI, antihistamine, or dopamine-blocking agent), the clinician may consider switching to an alternative that does not exacerbate RLS.
• Management of comorbid conditions: Optimizing treatment for diabetes, kidney disease, or thyroid dysfunction can improve secondary RLS.

2. Non-Pharmacological Interventions

Behavioral and lifestyle modifications are recommended for all individuals with RLS, regardless of severity:

• Sleep hygiene optimization: Maintaining a regular sleep schedule, creating a comfortable and cool sleep environment, and avoiding stimulating activities before bed.
• Exercise: Regular moderate-intensity exercise (such as walking, cycling, or swimming) has been shown to reduce RLS symptom severity. However, intense exercise close to bedtime may temporarily worsen symptoms.
• Reducing or eliminating caffeine, alcohol, and nicotine: These substances can aggravate RLS in many individuals.
• Leg massage, warm baths, or cold compresses: These can provide temporary symptomatic relief.
• Mental engagement activities: Some individuals find that engaging in absorbing mental activities during symptom episodes (such as puzzles or conversation) can partially reduce the perceived intensity of symptoms.
• Pneumatic compression devices: FDA-cleared devices that apply intermittent pressure to the legs have shown benefit in controlled trials.

3. Pharmacological Treatment

When symptoms are moderate to severe and insufficiently controlled by non-pharmacological measures and iron repletion, medication may be appropriate. Current evidence-based pharmacological options include:

• Alpha-2-delta calcium channel ligands (gabapentin enacarbil, pregabalin, gabapentin): These are now considered first-line pharmacological treatment by most expert consensus guidelines, including those from the IRLSSG and the American Academy of Sleep Medicine (AASM). They are effective for RLS symptoms and associated sleep disturbance and do not carry the risk of augmentation (see below). Gabapentin enacarbil (Horizant) is specifically FDA-approved for moderate-to-severe RLS.
• Dopamine agonists (pramipexole, ropinirole, rotigotine patch): These were previously considered first-line agents and remain effective for symptom control. However, their use has been tempered by the significant risk of augmentation — a treatment-emergent worsening of RLS where symptoms begin earlier in the day, spread to other body parts, or become more intense. Augmentation occurs in an estimated 30–70% of patients on long-term dopamine agonist therapy. For this reason, if dopamine agonists are used, they should be prescribed at the lowest effective dose.
• Low-dose opioids: For severe, refractory RLS, low-dose opioids (such as oxycodone/naloxone extended-release) have demonstrated efficacy in clinical trials. These are reserved for cases that have not responded to other treatments and require careful monitoring due to risks of dependence and respiratory depression.
• Benzodiazepines (clonazepam): Occasionally used to aid sleep in RLS patients, though they do not directly address the underlying sensorimotor symptoms and carry risks of dependence and daytime sedation.

Important note on augmentation: Augmentation is the most significant complication of long-term dopamine agonist therapy for RLS. It is not a failure of the medication to work, but rather a paradoxical worsening caused by the medication itself. If augmentation develops, the recommended approach is typically to gradually taper and discontinue the dopamine agonist (which can cause temporary symptom flares), ensure iron stores are adequate, and transition to an alpha-2-delta ligand or other non-dopaminergic treatment.

The long-term course of Restless Legs Syndrome varies considerably depending on its type, severity, and underlying cause:

• Primary RLS is generally a chronic, lifelong condition. In many individuals, symptoms gradually progress in frequency and severity over years to decades, though the rate of progression is highly variable. Some people experience periods of remission lasting weeks to months, particularly earlier in the disease course.
• Secondary RLS often has a more favorable prognosis. When the underlying cause is identified and effectively treated — such as correcting iron deficiency, adjusting a causative medication, or delivering a baby in pregnancy-related RLS — symptoms may partially or fully resolve.

With appropriate management, the majority of individuals with RLS can achieve meaningful symptom control and substantial improvement in quality of life. However, several factors influence prognosis:

• Early onset (before age 40): Often associated with a stronger genetic component and a more gradual, slowly progressive course.
• Late onset (after age 40): May progress more rapidly and is more likely to have identifiable secondary causes.
• Treatment response: Most individuals respond well to first-line treatments, particularly iron repletion and alpha-2-delta ligands. A minority have severe, treatment-refractory symptoms that require combination therapy or specialized management.
• Augmentation management: For individuals who develop augmentation from dopamine agonists, the transition to alternative treatments can be challenging in the short term but typically leads to improved long-term outcomes.

The psychological impact of RLS should not be underestimated. Chronic sleep disruption and persistent physical discomfort take a cumulative toll on emotional well-being. Studies have found that individuals with moderate-to-severe RLS report quality of life impairments comparable to those seen in other chronic conditions such as type 2 diabetes and osteoarthritis. Addressing the mental health dimensions of RLS — including screening for and treating comorbid depression and anxiety — is an integral part of comprehensive care.

Restless Legs Syndrome frequently co-occurs with or is related to several other medical and psychological conditions. Understanding these connections is important for comprehensive assessment and management:

• Periodic Limb Movement Disorder (PLMD): While the vast majority of individuals with RLS also have periodic limb movements of sleep (PLMS), PLMD is a separate diagnosis given when PLMS cause clinically significant sleep disturbance or daytime impairment in the absence of RLS. The two conditions share pathophysiological mechanisms involving dopaminergic dysfunction.
• Insomnia disorder: Chronic difficulty initiating sleep is one of the most common consequences of RLS and may meet criteria for a comorbid insomnia diagnosis. Cognitive behavioral therapy for insomnia (CBT-I) can be a helpful adjunctive treatment.
• Depression and anxiety disorders: Research consistently demonstrates elevated rates of major depressive disorder and generalized anxiety disorder among individuals with RLS. This relationship appears bidirectional — poor sleep worsens mood, and certain antidepressant medications used to treat depression can exacerbate RLS.
• Attention-Deficit/Hyperactivity Disorder (ADHD): A growing body of research indicates a significant association between RLS and ADHD, particularly in children and adolescents. Sleep disruption from RLS can produce daytime symptoms — inattention, hyperactivity, and impulsivity — that overlap substantially with ADHD. Some researchers suggest that a subset of children diagnosed with ADHD may have unrecognized RLS contributing to their symptoms.
• Iron deficiency anemia: While iron deficiency can exist without anemia, frank iron deficiency anemia is a well-established secondary cause of RLS and should always be evaluated.
• Peripheral neuropathy: Neuropathic conditions, particularly those associated with diabetes or small fiber neuropathy, frequently co-occur with RLS. Distinguishing neuropathic symptoms from RLS symptoms can be challenging and may require electrophysiological testing.
• Cardiovascular disease: Emerging research suggests an association between RLS (particularly when accompanied by PLMS) and increased cardiovascular risk, including hypertension and coronary artery disease. The mechanisms are not fully established but may involve sympathetic nervous system activation from repeated limb movements and sleep fragmentation.
• Fibromyalgia: Individuals with fibromyalgia have elevated rates of RLS. Both conditions involve central sensitization and sleep disturbance, and their co-occurrence can significantly compound functional impairment.

If you experience an uncomfortable urge to move your legs that follows the characteristic pattern described in this article — worsening during rest, improving with movement, and occurring predominantly in the evening or night — it is worth discussing these symptoms with a healthcare provider, even if they seem minor. Many people live with RLS for years before seeking evaluation, often because they assume their symptoms are normal or not "serious enough" to warrant medical attention.

You should seek professional evaluation promptly if:

• Leg discomfort or restlessness regularly interferes with your ability to fall asleep or stay asleep
• You experience persistent daytime fatigue, sleepiness, or difficulty concentrating that affects your work, relationships, or safety (e.g., drowsy driving)
• You notice mood changes — increased irritability, sadness, hopelessness, or anxiety — that you suspect may be related to poor sleep
• Your bed partner reports that you kick, jerk, or twitch during sleep
• Symptoms are spreading to your arms or other body parts, or are beginning earlier in the day (which may indicate augmentation if you are taking a dopamine agonist)
• Over-the-counter antihistamines, supplements, or home remedies are not providing adequate relief
• You are pregnant and experiencing new or worsening leg restlessness that disrupts sleep
• A child in your care complains of leg discomfort at bedtime, has difficulty sitting still, or experiences "growing pains" that follow a rest-related, evening-predominant pattern

The most appropriate starting point for evaluation is your primary care provider, who can conduct initial assessment and laboratory testing. For complex or treatment-resistant cases, referral to a sleep medicine specialist or neurologist with expertise in movement disorders is recommended.

Remember: The information in this article is educational and informational. It is not a substitute for professional medical evaluation, diagnosis, or treatment. If you recognize patterns consistent with Restless Legs Syndrome in your own experience, a qualified healthcare professional can provide a thorough assessment and develop a personalized treatment plan.